Grupo Biotoscana announces closing of Sale of Control

Sale of Control – Closing


Montevidéu, November 29th, 2019 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, in addition to the Material Facts of October 21st and 28th, 2019, hereby informs that it was notified by Knight Therapeutics Inc. (“Knight”), through its wholly owned subsidiary 11718991 Canada Inc. (“Buyer”), that the closing of the sale of 51,21%[1] of the shares issued by GBT (“Sale of Control”) has occurred on this date.

As previously announced, the Buyer confirmed it will conduct the mandatory tender offer for the acquisition of the remaining shares and BDRs of GBT, as set forth in Article 12 of the Bylaws of GBT, in similar terms of the Sale of Control (“MTO”).

Finally, the new composition and election of the members of the Company’s Board of Directors, approved by the shareholders’ meeting of November 25th, 2019 are in full force and effect as of this date.

The Company will keep its shareholders and the market in general informed on the developments of the events mentioned in this material fact, in compliance with applicable legislation, including all details related to the MTO.

[1] Excluding shares/BDRs held in treasury.

See the full article.


About GBT Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit